HBP — Helix Biopharma Share News
0.000.00%
Last trade - 00:00- CA$75.61m
- CA$73.13m
Brief: Helix Biopharma Intends To File Interim Consolidated Financial Statements By July 30
Brief: Helix Biopharma To Divest Remaining Ownership Of Polish Subsidiary
Brief: Helix Biopharma Says Expects To File Interim Disclosure Documents By July 30, 2020
Brief: Helix Biopharma Says L-Dos47 Phase I Lung Cancer Trial Data To Be Released At Asco 2020
Brief: Helix Biopharma Expects Patient Enrollment Will Be Impacted Due To COVID-19
Brief: Helix Biopharma Reports Q1 Loss Per Share C$0.02
Brief: Helix Biopharma Commences L-Dos47 Phase Lb/Ll Pancreatic Cancer Clinical Study
Brief: Acquisition Of Units Of Helix Biopharma Corp.
Brief: Helix Biopharma Corp Receives U.S. FDA Approval For Pancreatic Trial
Brief: Helix BioPharma Corp Submits L-DOS47 IND Application With U.S. FDA For Pancreatic Cancer
Brief: Helix Biopharma Q3 Loss Per Share C$0.02
Brief: Helix Biopharma Corp - L-Dos47 Phase Ii Randomized Study Advances To Second Cohort
Brief: Helix Biopharma Retains U.S. Legal And Capital Firms To Advise On U.S. Listing
Brief: Helix Biopharma Reports Q2 Loss Per Share Of C$0.03
Brief: Helix Biopharma Corp Provides Clinical Development And Strategic Corporate Update
Brief: Helix Biopharma Corp extends annual meeting date
Brief: Helix Biopharma Corp. Provides Strategic Update On L-Dos47 Clinical Program
Brief: Helix Biopharma Extends Period To Exercise Warrants
Brief: Helix Biopharma Corp. And Moffitt Cancer Center Extend Collaboration On Immunotherapy, Including Study Of L-Dos47 With Pd-1/Pd-L1 Inhibitors